[PDE5 inhibitors in treatment of benign prostatic syndrome]

Urologe A. 2007 Sep;46(9):1189-92. doi: 10.1007/s00120-007-1478-3.
[Article in German]
No abstract available

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Carbolines / therapeutic use*
  • Cell Division / drug effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Imidazoles / therapeutic use*
  • Isometric Contraction / drug effects
  • Male
  • Middle Aged
  • Muscle, Smooth / drug effects
  • Organ Culture Techniques
  • Phosphodiesterase 5 Inhibitors*
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / therapeutic use*
  • Prospective Studies
  • Prostate / drug effects
  • Prostatic Hyperplasia / drug therapy*
  • Purines / therapeutic use
  • Rats
  • Sildenafil Citrate
  • Stromal Cells / drug effects
  • Sulfones / therapeutic use*
  • Syndrome
  • Tadalafil
  • Triazines / therapeutic use
  • Urethra / drug effects
  • Urinary Bladder / drug effects
  • Vardenafil Dihydrochloride

Substances

  • Carbolines
  • Imidazoles
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride
  • Tadalafil
  • Sildenafil Citrate